Just months after Pfizer slashed hundreds of jobs in its own neuroscience R&D program, the pharmaceutical giant is making notable investments in two Boston-based neuroscience startups.
The company announced Wednesday that Tevard Biosciences and QurAlis will each receive one of Pfizer’s coveted “Golden Tickets”— a valuable voucher for the fees associated with renting a spot for one scientist for one year at LabCentral, a biotech incubator in Cambridge, Mass. For companies based elsewhere, the ticket also allows a startup to set up shop at the noted space in Kendall Square.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
